Scancell Hldgs Share Price (SCLP)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Scancell Hldgs	LSE:SCLP	London	Ordinary Share	GB00B63D3314	ORD 0.1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	+0.00p	+0.00%	13.25p	152,248	15:24:09

Bid Price		Offer Price	High Price	Low Price	Open Price
13.00p		13.50p	13.50p	13.25p	13.25p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology		-4.50	-1.36		51.4

Related Shares
GlaxoSmithKline (GSK), AstraZeneca (AZN), Geiger Count. S (GCS), Port Erin (PEBI)

Scancell Hldgs (SCLP) Latest News

Scancell Hldgs News

Date	Time	Source	Headline
18/9/2018	07:02	UKREG	Scancell Holdings Plc Notice of Final Results
10/8/2018	07:06	ALNCF	Alliance News Flash Headline
10/8/2018	07:00	UKREG	Scancell Holdings Plc Board Change
09/8/2018	11:57	ALNC	Scancell Extends Cancer Treatment Collaboration In Sweden
09/8/2018	07:00	UKREG	Scancell Holdings Plc Agreement
25/7/2018	14:45	UKREG	Scancell Holdings Plc Director/PDMR Shareholding
24/7/2018	07:01	UKREG	Scancell Holdings Plc Issue of Equity
18/7/2018	13:59	ALNC	Scancell To Use Ichor TriGrid System For Phase 2 Inhibitor Blend Study
18/7/2018	07:00	UKREG	Scancell Holdings Plc Scancell exercises TriGrid commercial option
23/5/2018	14:29	ALNC	Scancell To Receive European Patent For Moditope Platform In June

More Scancell Hldgs News

Scancell Hldgs Takeover Rumours

Scancell Hldgs (SCLP) Share Charts

1 Year Scancell Hldgs Chart

1 Month Scancell Hldgs Chart

Intraday Scancell Hldgs Chart

Scancell Hldgs (SCLP) Discussions and Chat

Scancell Hldgs Forums and Chat

Date	Time	Title	Posts
20/9/2018	15:21	Using immunology to fight cancer.	17,737
09/7/2018	12:26	Could this be the end of cancer?	761
20/5/2018	17:25	Scancell short thread	2
22/8/2016	08:20	Question	11
16/8/2014	08:47	Using immunology to fight cancer (LTH W/O Rose Tints - Free Speech Thread)	161

Add a New Thread

Scancell Hldgs (SCLP) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
15:03:24	13.15	30,000	3,945.00	O
14:53:56	13.17	15,000	1,974.90	O
14:20:02	13.31	5,000	665.50	O
11:41:35	13.31	3,880	516.43	O
11:27:00	13.88	2,118	293.98	O

View all Scancell Hldgs trades in real-time

Scancell Hldgs (SCLP) Top Chat Posts

Date	Subject
20/9/2018 09:20	Scancell Hldgs Daily Update: Scancell Hldgs is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell Hldgs was 13.25p. Scancell Hldgs has a 4 week average price of 11.50p and a 12 week average price of 11p. The 1 year high share price is 19.25p while the 1 year low share price is currently 9.50p. There are currently 387,796,556 shares in issue and the average daily traded volume is 243,134 shares. The market capitalisation of Scancell Hldgs is £51,383,043.67. Read Full Thread Reply
23/8/2018 11:57	gazza: Inan, You must be able to see why you wind people up. You said: " and what is achieved by this speculation ? " Why can't other people speculate and discuss things? It's OK for you to speculate on the share price, speculate on the timing of the share price, speculate on the future structure of the company, speculate on the trial results, speculate on the efficacy of the science, speculate on the competitors respone..... etc etc but it's not OK for ANYONE ELSE to! Answer me a simple question: Is it the people or the topic that you object to? Or both? Read Full Thread Follow Reply
23/8/2018 07:57	tosh123: Just to be clear, NO ONE as far as im aware has advocated to sell, especially not at these distressed levels, so lets leave that particular avenue of nonsense. As far as trading the ups and downs are concerned, absolutely. Anyone that hasn't done so over the last few years needs their bumps felt. The lack of corporate know how at board level should have been the indicator to anyone invested, that this share was going nowhere quick. We are all invested in the HOPE, that at some stage there will be a deal. When / if that deal eventually comes, and at what price, nobody can predict, its impossible. Years ago i called for DE and RG to be removed. Between them, they stifled any share price growth, and i have it on good authority, that they also had very conflicting views as to how to take the company forward. Ultimately one of them had to go, and that was DE. Unfortunately, IMHO, the wrong guy went, i would rather have retained DE, as i believe that his vision for the company was far more aligned to my own, and also those of many other shareholders. We will never really know what went on, or indeed what influence, if any, our II's had over the decision of who should leave. So here we are, many years later, with a share price that is pathetic, and also having suffered major dilution as well. Hopefully, the new BOD can do what RG and DE failed to do, and that is to get a deal over the line. Read Full Thread Follow Reply
09/8/2018 13:22	j777j: Scancell Holdings part of the new cancer revolutionShare 12:48 09 Aug 2018The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncologyINVESTMENTOVERVIEW: SCLPTHE BIGPICTUREThe company's innovations have shown some early promise - particularly SCIB-1, which has been used with some success to treat melanomaThe fight against cancer has moved into a new phase as drugs are developed that use the body's immune system to tackle the killer disease.And AIM-listed Scancell Holdings (LON:SCLP) is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise.In May investors got behind the business, backing a placing and open offer of new shares that brought in £8.7mln before expenses.Bankrolling development That cash will fund early clinical trials of a drug generated using its Moditope platform as well as supporting the development of its more advanced assets.They are SCIB-1 and SCIB-2, which target and stimulate existing cells that make up the body's defence mechanisms.At the turn of the year, Scancell reported the "compelling" results of a phase I/II trial of SCIB-1, and the immunotherapy has continued to impress since.Meanwhile, last December Cancer Research UK agreed to fund and sponsor a phase I/II lung cancer clinical study of its SCIB-2 vaccine in combination with another type of drug called a checkpoint inhibitor.Lung cancer is a killerLung cancer remains one of the most difficult cancers to treat and accounts for more than a quarter of all cancer deaths.That's more than breast, prostate and colon cancers combined. Around 228,000 people receive a lung cancer diagnosis in the US alone and more than 160,000 will not survive.A read-out from the study is expected in the first half of next year.ImmunoBody and Moditope Both SCIB-1 and SCIB-2 emerged from Scancell's ImmunoBody platform.MODI-1 is its first drug using the company's Moditope technology. Initially, it will be deployed in the clinic to treat breast and ovarian cancers as well as sarcoma (tumours found in fat, muscle, bone and tendons).MODI-1 acts to stimulate the production of killer CD4+ T cells that seek out and kill tumour cells that would otherwise be hidden from the immune system. Partnership renewedScientists at the Karolinska Institute, led by Professors Lars Klareskog and Vivianne Malmström, uncovered an essential role for citrullinated proteins, which are normally associated with arthritis, in this process.On Thursday (Aug 9), the company extended its collaboration with the rheumatology of the Swedish medical research university.The share price, which has fluctuated between 10-16p in the past year, appears to have found a level recently around 12p.At that price, the company is worth just under £44mln. Whether this is a fair valuation of the business is open to interpretation.Hard to valueNormally, you would carry out discounted cash flow analysis to assess just what Scancell's assets are worth.But as Hardman, the City research house pointed out in a recent note, the company's innovations are too early stage to be subjected to this sort of analysis.Instead, it's probably worth looking at the trends within the industry and the deals being done.Last year there were 35 transactions in the oncology sector in excess of US$1bn, according to EvalutePharma,Of that total, 32 were focused on immuno-oncology. In other words, this is a particularly active (and potentially rewarding) area of R&D.As Hardman analyst Martin Hall said in his note: "Scancell's proprietary technologies are in the 'hot' area of immuno-oncology and targeting markets of significant unmet medical need."Recent deals have demonstrated the price that big pharma is willing to pay for validated assets in the field." Read Full Thread Follow Reply
30/5/2018 08:01	tosh123: Torquay, none of the above justifies the 100% failure to deliver anything on time, and indeed even more significantly, failure to deliver many things at all. There have been numerous occasions where we have been told that its a " pivotal year " and that deals will be done, yet here we are some 6 - 7 years later, with a distressed share price, numerous dilutions, and potentially still looking at another 18 months to 2 years, before we may see any major shift in the share price. Whilst i appreciate the world of baby bio's is always evolving, this is Scancells core business, and as such, they should know their market. Delays are inevitable especially when you're talking about in depth trials, however, just for once it would be nice to see a realistic time frame announced, followed by an EARLY , or at least, on time, delivery. That said, as you rightly point out, the big buy back on all of the above, is the retention of all the IP, however, that IP is only really worth substantial money once the concepts behind the IP have been proven and verified, which we are still some way off, hence the 18 month - 2 years, before IMHO , we see any share price movement ABOVE the existing highs of a few years ago. Managed badly ???? Yes i think so, very badly. But im still here, and so are many other LTH's, so we all have faith, even if that faith is of varying magnitudes. Read Full Thread Follow Reply
30/5/2018 07:30	torquayfan: P7. Developing pre-clinical science and initiating clinical trials is a little different from say, building a house or making widgets - Scancell as a Biotech are surely not alone in setting targets which are then hard to attain. I daresay that BoD have met a few timescales but you go trawling for them if you have time. I mentioned the problem of ''managing a bundle of ever expanding and increasingly patented science with a tiny Team'' and I think it a fair point, particularly given the depth and range of Scancell's science portfolio! If all Scancell had now was SCIB1 for example - I'm guessing we'd be further along but that'd be on a much smaller path ? As for BoD supporting the share price - their main business is to take the science through the 'maze' to commercialisation in some way - it's not proving easy with limited resources but Scancell ARE getting there. Just look what's on board now ! Of course, BoD HAVE tried in many ways to support the share price - but this is Biotech UK and this it is the way it is. Hard going. But at least the IP has so far been retained. What Scancell have put together is a truly amazing achievement and well done the BoD - the share price will zoom in due course. Of that I am certain. ATB Read Full Thread Follow Reply
24/5/2018 09:57	panama7: RH, the share price is consolidating at 14p, the share price was 34p when Goodfellow released his video, the BOD should have been ethically and morally obligated to keep the share price above that price. they have left those unfortunate Investors out of pocket for 5 years and counting and have shown by their words , actions and deeds they couldn't care less about their PI's. Read Full Thread Follow Reply
22/5/2018 12:54	gazza: Is selling a good thing? Inan, Try, if you can, to get your head round it, I will try and make it simple for you: When I did economics in nursery skool many years ago, we learned the funamental principle of price is determined by supply and demand. Plentiful supply and low demand would cause the price to fall. On the other hand, limited supply and high demand would cause the price to rise. Now here's the thing: What would happen if there was NO supply (ie, no sellers)? There would be no price, no trades happening that would cause the price to move either UP or DOWN. In the case of a share, if noone sold, noone could buy either and the share price would stagnate. This is what is meant by LIQUIDITY, it is not what happens in your head or should I say thou head? What WE need, as shareholders in SCLP is plenty of eager buyers whose apetite for shares is met by some sellers. In this scenario, the price may even go up. Read Full Thread Follow Reply
06/3/2018 15:01	tosh 123: Ineptico.... I stand by both of those posts... I'm really not sure what point you're trying to prove... are you going mad or something ? Scancell is all about potential, otherwise there would be no need for any further trials, or any further funding, as we would be generating revenue and paying a dividend ! Which bit of that most basic of business principle don't you get ? The market ( which is currently what determines the share price ) is well aware of THE RISKS ( as are the BOD ) hence the share price is where its at.. simple ! It is all about risk vs reward, as it is with EVERY investment... and the BOD are , by their own admission, trying to reduce the risk, and thereby, encourage an increase in the share price... Contrary to your now " proven to be totally wrong " posts that there is no risk. Read Full Thread Follow Reply
30/12/2017 14:46	drdobson1: ONW-Personally thought what a great post. I have been thinking along same lines re Inanaco.Is he a lot cleverer than I have given him credit for. Create the impression of being a long term holder but all the time is he has been trading SCLP-probably only revealed when his ego could not cope with the beating it was taking from the declining share price and he thought I have to be seen as a much better investor/trader than the ASTUTE. On the VAL board he was called a shorter and that he and C7 were part of a boiler room crew.Well I thought that a load of nonsense but perhaps he is a secret trader as you say that stock is a lot more volatile than here. Good traders are often perceived as being devious and only out for themselves and he certainly fits that bill By portraying himself as a self taught science guru he has sought to distract from his game plan which is to destroy investor sentiment and cause maximum bulletin board disharmony. He probably wants to get the SCLP share price to fall so he can buy and trade in fact he may not have much of a holding at all. He is as cunning as a cartload of monkeys and slippery as an eel and has me totally fooled or am I being too kind t9 him. Anyway all have a happy new year Read Full Thread Follow Reply
23/11/2017 16:00	inanaco: ""if you make a statement that i cannot reason against then your statement becomes the lead policy which i then support "" yes because most of the intense discussion are on the science that impact IP value """There are plenty. Here's just one: share price down from 60p to 12p. Isn't that a negative? I make it negative 48p."""" That's sentiment has the science stood still in all that time, ? ""the Shareprice is not relevant as all i am trying to show is it's cheap relative to the IP.<<br /> Two fatal flaws in one sentence: 1) How on earth can you say the share price isn't relevant??!! It is very relevant if you have invested and need to sell.""" You have now added a third party ie somebody that needs to sell, that is not my position. """It is relevant to how easy it is for SCLP to raise new funds and at what price those funds are raised and therefore relevant to the amount of dilution of our investment.""" Very true, But like you have done, you can then look at the shares in issue and assess the likely outcome of capital growth based on the resultant influx of cash and how the science develops from that Dilution so has a result on both sides of the equation Ie A bigger increase in capital growth than was forecast without that expenditure. """ all i am trying to show is it's cheap relative to the IP.<<br /> Well you haven't! """ I have but maybe you have not understood the years of comparing and understanding of the science of others with wildforce allowed us to pretty well place Scancell into the market place and place reasoned value to the IP """" lozan/Tosh, Mr W cannot explain why the IP has a lower value to the share price <<br /> The IP has a lower value to the SP? Are you saying the IP is not worth 12p? """ actually the buying of the share by Loz at 47p and selling at 53p would indicate Loz buying at the level was cheap and selling at 53p produced a true value event. to then argue its only worth 12p with that evidence would be difficult ... but Loz would have to show comparative value to the IP .. being 12p .. which i suspect would be impossible """not a point worth discussing as No conclusion will be ever drawn from it as its not linked to IP only market sentiment on any particular day ...<<br /> You have a point, why worry about a share price of 12.3 when it could easily be 12.5 tomorrow."" I am not worried about the share price, i already feel the value way exceeds this level, and indeed the Board of Scancell accept that, hence they want to raise the big amounts not based on share price but IP .. however they will always have the fall back position of market priced cash raising which again is Not Ip priced cash raising like a deal """thus all the posts can be dismissed as not relevant, <<br /> In YOUR opinion, which here does not command a very high level of respect"""" then show me posts that you feel are of High Value that i have missed, like i said I debate for my own investment position ..I defend Scancell because I am invested not because your invested, Read Full Thread Follow Reply

Scancell Hldgs share price data is direct from the London Stock Exchange

add chat code

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:42 V: D:20180920 16:05:59